Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poseltinib
- Development stage
- Phase 2
- Lead developer
- Novomedison
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Poseltinib is an experimental small molecule inhibitor of Bruton's tyrosine kinase (BTK), developed for the treatment of autoimmune and inflammatory diseases. By irreversibly and covalently inhibiting BTK, poseltinib blocks B-cell receptor signaling pathways, thereby suppressing B-cell activation and downstream inflammatory responses. It was originally developed by Hanmi Pharmaceutical and later licensed to Eli Lilly for further development. Clinical trials have focused on rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, Sjögren's syndrome, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and relapsed or refractory primary central nervous system lymphoma[2][3][4][9].
- Brand names
- poseltinib
- Other names
- Poseltinib [INN]N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
02
Targets
JAK3 (Janus kinase 3)BMX (Bone Marrow Tyrosine Kinase X-linked)ITK (Interleukin 2-inducible T-cell kinase)BTK (Bruton tyrosine kinase)TXK
Beyond the preview
Go deeper on poseltinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poseltinib.